BlackRock’s Lipocine LPCN Stock Holding History

BlackRock’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$713K	Hold	89,272	–	–	﹤0.01%	4438
2025 Q4	$717K	Hold	89,272	–	–	﹤0.01%	4396
2025 Q3	$254K	Hold	89,272	–	–	﹤0.01%	4631
2025 Q2	$282K	Hold	89,272	–	–	﹤0.01%	4588
2025 Q1	$284K	Hold	89,272	–	–	﹤0.01%	4541
2024 Q4	$436K	Hold	89,272	–	–	﹤0.01%	4447
2024 Q3	$401K	Hold	89,272	–	–	﹤0.01%	4380
2024 Q2	$736K	Buy	89,272 +14,750	+20%	+$92.2K	﹤0.01%	4256
2024 Q1	$388K	Sell	74,522 -324	-0.4%	-$1.26K	﹤0.01%	4444
2023 Q4	$209K	Hold	74,846	–	–	﹤0.01%	4628
2023 Q3	$223K	Sell	74,846 -5,452	-7%	-$22.9K	﹤0.01%	4647
2023 Q2	$405K	Sell	80,298 -6,021	-7%	-$28.3K	﹤0.01%	4541
2023 Q1	$467K	Buy	86,319 +374	+0.4%	+$2.89K	﹤0.01%	4542
2022 Q4	$581K	Buy	85,945 +359	+0.4%	+$2.62K	﹤0.01%	4572
2022 Q3	$655K	Sell	85,586 -9,296	-10%	-$104K	﹤0.01%	4635
2022 Q2	$1.29M	Buy	94,882 +2,841	+3%	+$44.3K	﹤0.01%	4430
2022 Q1	$2.14M	Sell	92,041 -1,756	-2%	-$36.7K	﹤0.01%	4358
2021 Q4	$1.58M	Buy	93,797 +825	+0.9%	+$15.3K	﹤0.01%	4495
2021 Q3	$1.72M	Sell	92,972 -111	-0.1%	-$2.45K	﹤0.01%	4375
2021 Q2	$2.21M	Sell	93,083 -2,378	-2%	-$55.9K	﹤0.01%	4228
2021 Q1	$2.45M	Buy	95,461 +231	+0.2%	+$6.67K	﹤0.01%	4227
2020 Q4	$2.2M	Buy	95,230 +483	+0.5%	+$11.6K	﹤0.01%	4005
2020 Q3	$2.27M	Buy	94,747 +52,212	+123%	+$1.39M	﹤0.01%	3870
2020 Q2	$911K	Sell	42,535 -4,844	-10%	-$62.8K	﹤0.01%	4065
2020 Q1	$386K	Buy	47,379 +1,861	+4%	+$14.7K	﹤0.01%	4106
2019 Q4	$298K	Buy	45,518 +23,574	+107%	+$604K	﹤0.01%	4259
2019 Q3	$1.05M	Buy	21,944 +521	+2%	+$20.9K	﹤0.01%	3962
2019 Q2	$710K	Buy	21,423 +3,149	+17%	+$97.2K	﹤0.01%	4112
2019 Q1	$717K	Buy	18,274 +246	+1%	+$7.55K	﹤0.01%	4014
2018 Q4	$399K	Buy	18,028 +305	+2%	+$7.08K	﹤0.01%	4107
2018 Q3	$416K	Buy	17,723 +84	+0.5%	+$2.07K	﹤0.01%	4163
2018 Q2	$390K	Sell	17,639 -2,318	-12%	-$55.3K	﹤0.01%	4162
2018 Q1	$519K	Sell	19,957 -243	-1%	-$6.76K	﹤0.01%	4040
2017 Q4	$1.18M	Buy	20,200 +259	+1%	+$16.1K	﹤0.01%	3854
2017 Q3	$1.34M	Buy	19,941 +2,891	+17%	+$209K	﹤0.01%	3816
2017 Q2	$1.17M	Sell	17,050 -40,285	-70%	-$2.63M	﹤0.01%	3817
2017 Q1	$3.8M	Buy	57,335 +57,296	+146,913%	+$3.71M	﹤0.01%	3469
2016 Q4	$2K	Hold	39	–	–	﹤0.01%	3644
2016 Q3	$3K	Hold	39	–	–	﹤0.01%	3567
2016 Q2	$2K	Buy	+39	New	+$6.04K	﹤0.01%	3643

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock's LPCN Position: Q1 2026 in Review

BlackRock held its Lipocine (LPCN) position steady in Q1 2026 at 89,272 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #4438.

BlackRock first reported a position in LPCN in Q2 2016 and has held it in 40 quarters since. The position peaked at $3.8M in Q1 2017. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

BlackRock held 89,272 shares of Lipocine worth $713K as of Q1 2026.
BlackRock left its Lipocine share count unchanged in Q1 2026.
Lipocine made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4438 holding.
BlackRock first reported a position in Lipocine in Q2 2016 and has held it in 40 quarters since.
BlackRock's Lipocine position peaked at $3.8M in Q1 2017.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.